S&CO Inc. Acquires Shares of 5,500 Penumbra, Inc. $PEN

S&CO Inc. bought a new stake in Penumbra, Inc. (NYSE:PEN) during the 2nd quarter, HoldingsChannel reports. The fund bought 5,500 shares of the company’s stock, valued at approximately $1,736,000.

Several other institutional investors have also recently made changes to their positions in the company. Hsbc Holdings PLC boosted its stake in shares of Penumbra by 2.3% during the 4th quarter. Hsbc Holdings PLC now owns 1,527 shares of the company’s stock worth $475,000 after purchasing an additional 35 shares during the period. Farther Finance Advisors LLC raised its position in Penumbra by 27.1% in the 4th quarter. Farther Finance Advisors LLC now owns 178 shares of the company’s stock worth $55,000 after purchasing an additional 38 shares during the period. Swiss Life Asset Management Ltd raised its position in Penumbra by 2.3% in the 4th quarter. Swiss Life Asset Management Ltd now owns 1,728 shares of the company’s stock worth $537,000 after purchasing an additional 39 shares during the period. Keybank National Association OH lifted its stake in Penumbra by 1.2% in the fourth quarter. Keybank National Association OH now owns 3,705 shares of the company’s stock worth $1,152,000 after purchasing an additional 43 shares during the last quarter. Finally, UMB Bank n.a. lifted its stake in Penumbra by 11.3% in the fourth quarter. UMB Bank n.a. now owns 442 shares of the company’s stock worth $137,000 after purchasing an additional 45 shares during the last quarter. Institutional investors own 88.88% of the company’s stock.

Penumbra Trading Up 0.0%

PEN stock opened at $326.91 on Friday. Penumbra, Inc. has a 12 month low of $221.26 and a 12 month high of $362.41. The firm’s 50-day moving average is $319.53 and its 200 day moving average is $328.85. The company has a market capitalization of $12.88 billion, a PE ratio of 80.32, a P/E/G ratio of 2.03 and a beta of 0.70. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.75 and a quick ratio of 3.86.

Penumbra (NYSE:PEN) last released its quarterly earnings data on Thursday, July 30th. The company reported $0.88 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.16 by ($0.28). The company had revenue of $390.05 million during the quarter, compared to analysts’ expectations of $389.64 million. Penumbra had a net margin of 10.67% and a return on equity of 10.50%. Penumbra’s quarterly revenue was up 14.9% on a year-over-year basis. During the same period last year, the firm earned $0.86 earnings per share. On average, research analysts anticipate that Penumbra, Inc. will post 5.02 EPS for the current year.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Evercore restated an “outperform” rating and set a $320.00 target price on shares of Penumbra in a research report on Monday, July 6th. Zacks Research downgraded Penumbra from a “hold” rating to a “strong sell” rating in a report on Monday, June 29th. Citigroup decreased their price target on Penumbra from $374.00 to $350.00 and set a “neutral” rating for the company in a research note on Thursday, May 7th. Wall Street Zen upgraded Penumbra to a “hold” rating in a report on Saturday, May 9th. Finally, Royal Bank Of Canada restated a “sector perform” rating and set a $374.00 price objective on shares of Penumbra in a report on Thursday, June 11th. Three equities research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $367.07.

Penumbra Profile

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.